These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators. JAMA; 2004 Nov 17; 292(19):2343-9. PubMed ID: 15547161 [Abstract] [Full Text] [Related]
5. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB. Circ Arrhythm Electrophysiol; 2008 Dec 17; 1(5):337-43. PubMed ID: 19808428 [Abstract] [Full Text] [Related]
7. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747 [Abstract] [Full Text] [Related]
10. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlöf B, LIFE Study Investigators. Hypertension; 2007 Nov 12; 50(5):984-90. PubMed ID: 17893425 [Abstract] [Full Text] [Related]
12. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM, LIFE Study Investigators. Am Heart J; 2003 May 12; 145(5):919-25. PubMed ID: 12766755 [Abstract] [Full Text] [Related]
19. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K. Am J Hypertens; 2012 Oct 12; 25(10):1101-9. PubMed ID: 22717544 [Abstract] [Full Text] [Related]